Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine Dose-Dependent Modulation of Lung Function and AQP1 Expression During One-Lung Ventilation
NCT07145814Completed
- Sponsor
- Guangxi Zhuang Autonomous Region People's Hospital
- Start
- Jan 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of dexmedetomidine in acute lung injury (ALI) (3 arms), sponsored by Guangxi Zhuang Autonomous Region People's Hospital. Primary endpoint: Aquaporin-1 expression. Started Jan 2018; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
acute lung injury (ALI)
Beyond the preview
Go deeper on NCT07145814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07145814.